Théa is an independent pharmaceutical company specialized in the research, development and commercialization of eye-care products.
Laboratoires Théa was founded by Henri CHIBRET, a fourth-generation member of a French ophthalmological dynasty, born in the nineteenth century. Set up in 1994 from an R & D start-up company, Théa has played an important role in the latest pharmacological advances and in less than 10 years has risen to become the leading independent eye-care group in Europe. Henri and Jean-Fréderic CHIBRET (a fifth generation member of the dynasty) have presided over the group since 2008.
Present in over 65 countries, particularly in Europe, North and Sub Saharan Africa, South America and the Middle East, Théa is proud of its roots in the Auvergne region of France. Its head office is based in the capital of the Auvergne (Clermont-Ferrand) and is at the heart of a network comprising almost 700 employees worldwide.
Contact
LABORATOIRES THÉA
12 Rue Louis-Blériot
63000 Clermont-Ferrand
email: http://www.laboratoires-thea.com/file.contacts.file/contacts.Contacts/lang.2/
Ana Fernández of Théa Spain discusses the strategic importance of the Spanish affiliate – the group’s oldest, current trends in Spanish ophthalmology, and what differentiates Théa – as a family-run…
Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third…
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such…
Hubert Mechin, president of AFCROs, the association that groups clinical research organisations in France, details the organisation’s efforts to help its members stay abreast of changes in the European regulatory…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
See our Cookie Privacy Policy Here
